PERSPECTA

News from every angle

← Back to headlines

Glaukos Projects $600M-$620M Sales by 2026 Driven by iDose TR and Epioxa

Glaukos has outlined a sales target of $600 million to $620 million by 2026, with growth expected to be driven by its iDose TR and Epioxa products.

16 Feb, 19:01 — 16 Feb, 19:01
PostShare

Sources

Showing 1 of 2 sources
YahooMostly Factual173d ago

Carriers anticipate pricing power while shippers plan for flexibility in 2026

Read full article →

Coverage Timeline

First report: Yahoo · 16 Feb, 19:01Full coverage: 2 · 1d 9hWindow: 1d 9h
Left-leaningCenterRight-leaning
Yahoo16 Feb, 19:01First to report

Carriers anticipate pricing power while shippers plan for flexibility in 2026

1d later
seeking-alpha18 Feb, 04:15Latest update

Glaukos outlines 2026 sales target of $600M–$620M as iDose TR and Epioxa drive growth momentum

Related Stories

Low Rhine Water Levels Impact German Economy

21m ago

South Pars Refineries Undergoing Reconstruction

22m ago

El Niño Returns, Raising Concerns for Global Agriculture

26m ago

Review of DFSK E5 Hybrid SUV

36m ago